Navigation Links
Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
Date:9/10/2009

cleCare.com.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. The personalized oncology services division assists physicians by maximizing personalized treatment options for their cancer patients through access to expert medical information panels and development of personalized Tumorgrafts from their patient's fresh tumor.

www.championsbiotechnology.com

www.personalizedcancertreatment.com

This press release contains "forward-looking statements
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
2. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
3. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
4. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
5. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
6. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
8. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
9. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
10. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
11. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... New York, NY (PRWEB) December 16, 2014 ... undergone significant changes since 2013, which is why IBISWorld ... one, this industry continues to benefit from an intensified ... 2014, the proposal for new emission standards for power ... affected industry operators. According to IBISWorld Industry Analyst Sarah ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 22020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... MINNEAPOLIS, Aug. 24, 2011 Cellectis bioresearch, the ... Cellectis (Alternext: ALCLS), and Recombinetics, a specialist in ... development and license agreement on the creation of ... accordance with biosafety and animal well-being requirements, large ...
... Pa., Aug. 24, 2011 Kibow Biotech, Inc. today ... and marketing agreement with the current licensing partner specializing ... 100% natural, probiotic dietary supplement indicated for the reduction ... severe renal failure. Developed by Kibow, Azodyl™ has been ...
... SPRING, Md., Aug. 24, 2011 United Therapeutics ... the completion of its FREEDOM-C(2) Phase 3 trial ... release oral formulation of treprostinil, a stable synthetic ... hypertension (PAH).  Preliminary analysis demonstrates that the trial ...
Cached Biology Technology:Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... “cautionary tale?about what may go wrong when using the fledgling ... , In the February 16 issue of the Journal of ... M. D. Anderson Cancer Center detail why an experimental test ... of blood is unlikely to lead to a reliable clinical ...
... what may go wrong when using the fledgling science of ... the February 16 issue of the Journal of the National ... Anderson Cancer Center detail why an experimental test intended to ... is unlikely to lead to a reliable clinical test right ...
... of,HIV infection per act of heterosexual sex among a ... have more,than twice the risk of acquiring HIV than ... 15 issue of The Journal of,Infectious Diseases, now available ... Kenya collected detailed sexual data from a,group of male ...
Cached Biology News:Signaling protein builds bigger, better bones in mice 2Signaling protein builds bigger, better bones in mice 3New species from old data 2New species from old data 3Male circumcision reduces risk of HIV transmission from women to men 2